argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

February 10, 2022 – argenx (Euronext & Nasdaq: ARGX), a global immunology company focused on severe autoimmune diseases, will participate in a fireside chat at the 11^th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 10:40 a.m. ET. A live webcast can be accessed on their Investors section of the argenx website, with a replay available for 90 days. argenx is known for developing the first approved neonatal Fc receptor blocker in the U.S. and Japan and is advancing various treatments for autoimmune diseases.

February 10, 2022

Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the 11^th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET.

A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 90 days following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S. and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram. 

For further information, please contact:

Media:

Kelsey Kirk
kkirk@argenx.com

Joke Comijn (EU)
jcomijn@argenx.com

Investors:

Beth DelGiacco
bdelgiacco@argenx.com

Michelle Greenblatt
mgreenblatt@argenx.com

FAQ

When will argenx participate in the SVB Leerink Global Healthcare Conference?

argenx will participate in the SVB Leerink Global Healthcare Conference on February 17, 2022, at 10:40 a.m. ET.

How can I access the webcast for argenx's presentation?

The live webcast of argenx's presentation can be accessed on their Investors section of the website.

What is argenx known for?

argenx is known for being the first company to develop an approved neonatal Fc receptor blocker in the U.S. and Japan.

What does argenx focus on in its research?

argenx focuses on developing treatments for severe autoimmune diseases through its Immunology Innovation Program.

How long will the replay of the webcast be available?

The replay of the webcast for argenx's presentation will be available for approximately 90 days following the event.